11/15/2024

Mitotech Presents New positive Animal Efficacy Data for SkQ1 in MASH Treatment at The 75th Liver Meeting

11/06/2024

Mitotech Unveils Promising New Obesity Treatment Data on SkQ1 at ObesityWeek 2024

09/17/2024

Mitotech Presents Promising Results in Friedreich’s Ataxia

04/29/2024

Mitotech to Present at LSX World Congress

10/11/2023

Mitotech CEO To Present At LSX Investival Showcase 2023

10/01/2023

Mitotech COO To Present At Bio Investor Forum 2023

09/21/2023

Mitotech CSO to present at Targeting Mitochondria 2023 Conference

10/13/2022

Essex Biotechnology Secures Exclusive Rights in Mitotech’s lead candidate SkQ1 for Ophthalmology

02/24/2022

Mitotech CSO to present at Mitochondria-Targeted Drug Development Summit

01/26/2022

Mitotech to Host Key Opinion Leader Webinar on Visomitin®: A Potential Treatment for Dry Eye Disease

12/15/2021

Mitotech granted Orphan Drug Designation by FDA for Visomitin® in LHON

05/06/2021

Mitotech's focus on opthalmology discussed in Fierce Biotech publication

03/04/2021

Mitotech CEO Natalia Perekhvatova to present at OIS Dry Eye Innovation Showcase 2021

02/26/2021

Mitotech and Essex Bio-Technology announce positive results of VISTA-2 Phase 3 clinical study in Dry Eye Disease

02/01/2021

Mitotech to present at LSX Congress 2021

01/11/2021

Mitotech Ltd To Present at Biotech Showcase Digital 2021 Conference

10/23/2020

Mitotech to present in Eyecelerator's Retina Livestream organized by AAO and ASCRS

08/25/2020

Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 – a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease

12/12/2019

Mitotech and Essex Bio-Technology Announce Enrollment in VISTA-2 - a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease

10/29/2018

Mitotech Completes First Patient Visit in VISTA-1 - Phase 2b/3 Clinical Study of SkQ1 for Dry Eye Disease

10/23/2018

Mitotech Initiates Phase 2b/3 Clinical Trial of SkQ1 Ophthalmic Solution in Patients with Dry Eye Disease in a Co-Development Effort with Essex Bio-Technology

07/19/2018

Mitotech partners with Essex Bio-Technology for a late-stage clinical program in Dry Eye Disease

10/24/2017

Mitotech announces new Dry Eye data set supporting SkQ1's novel mechanism of action

04/26/2017

Mitotech's SkQ1 improved visual acuity in Leber's Hereditary Optic Neuropathy (LHON) patients

04/20/2017

Mitotech's SkQ1 and its potential for treating age-related disorders discussed in Fierce Biotech publication

03/21/2017

Mitotech's lead compound significantly increased lifespan of rapidly aging mice

02/10/2017

Mitotech discusses SkQ1 and Dry Eye Disease in a recent Fierce Biotech article

02/07/2017

Mitotech will attend the Biotech and Money conference in London, Feb 7-8, 2017

01/20/2017

Mitotech Ltd Developing a Dry Eye Treatment has been Granted Two U.S. Patents for Pharmaceutical Formulations

09/09/2016

Mitotech Ltd is granted a patent in anti-aging

07/27/2016

Mitotech Ltd announces its Ophthalmic Scientific Advisory Board

03/20/2016

Oxidative stress and dry eye in Review of Ophthalmology

03/01/2016

Mitotech Ltd to present at ARVO 2016

02/05/2016

Mitotech CEO to present at the annual BIO CEO and Investor Conference 2016

01/25/2016

Mitotech Ltd to initiate its first clinical study of a systemic formulation of SkQ1

01/10/2016

Results of SkQ1 U.S. Phase 2 Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal

12/27/2015

Results of Mitotech's Multicenter Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal

10/16/2015

Mitotech Ltd to present at the 2015 Sofinnova Japan Biopharma Partnering Conference

05/03/2015

Mitotech's posters at ARVO 2015 in Denver, May 3-7

04/23/2015

Mitotech Announces Phase 2 Data Showing Positive Effect of SkQ1 in Patients with Dry Eye Syndrome

04/21/2014

Mitotech Ltd announces the initiation of Phase II clinical trial in Dry Eye Patients Utilizing the Controlled Adverse Environment

05/14/2013

Mitotech completes series of uveitis studies

12/09/2012

Mitotech's posters at ARVO 2015 in Denver, May 3-7

01/17/2012

Mitotech initiated pre-clinical program for SkQ1 compound in the U.S.